Published in Cancer Weekly, June 24th, 2003
The safety profile was manageable and was consistent with that previously observed in phase I and II studies.
Data from the phase II study were presented in a poster...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.